Nova Patents
IL231350B2

Use for and article of manufacture including her2 dimerization inhibitor pertuzumab

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

Every citation, both ways

Citations
ReferenceRelationCited during
HOFFMAN LA-ROSCH, A STUDY OF PERTUZUMAB IN COMBINATION WITH HERCEPTIN AND CHEMOTHERAPY IN PARTICIPANTS WITH HER2-POSITIVE BREAST CANCER, 20 September 2011 (2011-09-20)Non-patentSearch report
CHANG, HELENA R., ET AL., DIFFERENTIAL RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO A DOCETAXEL AND CARBOPLATIN?BASED NEOADJUVANT TREATMENT., 3 September 2010 (2010-09-03)Non-patentSearch report
GIANNI, L., ET AL., ABSTRACT S3-2: NEOADJUVANT PERTUZUMAB (P) AND TRASTUZUMAB (H): ANTITUMOR AND SAFETY ANALYSIS OF A RANDOMIZED PHASE II STUDY ('NEOSPHERE')., 15 December 2010 (2010-12-15)Non-patentSearch report
COUDERT, BRUNO P., ET AL., MULTICENTER PHASE II TRIAL OF NEOADJUVANT THERAPY WITH TRASTUZUMAB, DOCETAXEL, AND CARBOPLATIN FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-OVEREXPRESSING STAGE II OR III BREAST CANCER: RESULTS OF., 31 December 2007 (2007-12-31)Non-patentSearch report
SCHEUER, WERNER, ET AL., STRONGLY ENHANCED ANTITUMOR ACTIVITY OF TRASTUZUMAB AND PERTUZUMAB COMBINATION TREATMENT ON HER2-POSITIVE HUMAN XENOGRAFT TUMOR MODELS., 31 December 2009 (2009-12-31)Non-patentSearch report
GIANNI, L., ET AL., P301 ADDITION OF PERTUZUMAB (P) TO TRASTUZUMAB (H)-BASED NEOADJUVANT CHEMOTHERAPY SIGNIFICANTLY IMPROVES PATHOLOGICAL COMPLETE RESPONSE IN WOMEN WITH HER2-POSITIVE EARLY BREAST CANCER: RESULT OF A RANDOMISED PHASE II STUDY (NEOSPHERE)., 31 December 2011 (2011-12-31)Non-patentSearch report